Earlier this month, the Food and Drug Administration (FDA) approved Lexapro (escitalopram oxalate) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents 12- to 17-years-old.
Here's some basic information about the approval from a Forest Laboratories press release (I have put some parts in bold for added attention):
"The approval of Lexapro for the treatment of adolescent depression was supported by two placebo-controlled studies, one conducted in adolescent patients taking Lexapro and one conducted in children and adolescents taking citalopram (Celexa) . In an 8-week flexible- dose, placebo-controlled study that compared Lexapro 10-20 mg/day to placebo in 12 to 17 year old patients reported in 2008, Lexapro showed statistically significant greater mean improvement from baseline, compared to placebo, on the Children's Depression Rating Scale-Revised (CDRS-R).
In another 8-week, flexible-dose, placebo-controlled study, children and adol...
Altered neurotransmitter (serotonin, norepinephrine, and dopamine) levels are responsible for clinical depression symptoms in many people. Diets low in omega-3 and other fatty acids, folic acid, and vitamin B-12 appear to be risk factors for development of depression. Epidemiological research has confirmed a genetic link but particular causative genes have not been identified. Social or environmental factors are also implicated in depression. Clinical depression affects women (up to 20% of women will be affected at some point) at twice the rate of men, while gender does not influence the incidence in children. Adolescent girls are more likely to develop clinical depression than boys. The onset of clinical depression symptoms usually occurs between the ages of 20 to 50, but people over age 65 appear to be at risk also. The incidence of manic depression is not affected by gender in adults or children. A person with an immediate relative with bipolar disorder is 8 to 18-fold more lik...
Christos Ballas, MD, is an academic and forensic psychiatrist.
He graduated from Jefferson Medical College and completed his
residency at the Hospital of the University of Pennsylvania. He
joined the faculty of the University of Pennsylvania School of
Medicine as an Assistant Professor. He works as inpatient and
consult/liaison psychiatrist, in addition to maintaining a private
practice dedicated to forensics.
Dr. Ballas has published and lectured extensively. His medical
interests include forensic issues and violence, pharmacology, and
healthcare policy. Dr. Ballas is also a talented artist and a
technology enthusiast. One of his current projects include a novel
about the end of the internet.
Dr. Ballas looks forward to answering your questions about
depression. You can send your questions to
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.